MedTrace Logo

Safety and Efficacy of Herbal Tea in Type 2 Diabetics

NCT04054284 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-02-13

No results posted yet for this study

Summary

Nearly 25% of the world's population relies on traditional medicinal systems but for professionals their effectiveness and even more safety are the main concern. Therefore, the aim of this preliminary study is to assess safety and effectiveness of herbal tea mixture on the control of glycaemia in Type 2 diabetics.The mixture consists of nine plants which have well-documented traditional use for the control of glycaemia.

Conditions

Interventions

DIETARY_SUPPLEMENT

Antidiabetic Herbal Tea

Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.

DIETARY_SUPPLEMENT

Herbal Tea

Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.

Sponsors & Collaborators

  • Dom zdravlja Osijek (Health Centre Osijek)

    collaborator UNKNOWN

  • Osijek University Hospital

    collaborator OTHER

  • Josip Juraj Strossmayer University of Osijek

    lead OTHER

Principal Investigators

  • Ines Banjari, PhD · Department of Food and Nutrition Research, Faculty of Food Technology

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2020-02-10
Completion
2020-02-12

Countries

  • Croatia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04054284 on ClinicalTrials.gov